Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.73
-0.1900-6.51%
Post-market: 2.730.00000.00%16:04 EDT
Volume:1.47M
Turnover:4.00M
Market Cap:311.22M
PE:-2.05
High:2.89
Open:2.88
Low:2.66
Close:2.92
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:68.28M
Volume Ratio:0.90
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.96
PE(LYR):-1.95

Loading ...

Perspective Therapeutics: Merck Collaboration and 2H26 Catalysts Reinforce Buy Rating and Unchanged $11 Price Target

TIPRANKS
·
Yesterday

Perspective Therapeutics Price Target Maintained with a $11.00/Share by Wedbush

Dow Jones
·
Yesterday

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212PB]Psv359 in Combination with Keytruda® (Pembrolizumab) in Fap-Α Positive Solid Tumors

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics [212Pb]VMT-Α-NET Cohort Safety, Efficacy Data Set for ENA Symposium Poster Session

Reuters
·
Sep 11

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

GlobeNewswire
·
Sep 11

Perspective Therapeutics Updates Radiopharmaceutical Oncology Pipeline Outlook

TIPRANKS
·
Sep 09

Lantheus Alpha Therapy Disposes of USD 773,930 in Perspective Therapeutics Common Shares

Reuters
·
Sep 09

Lantheus Alpha Therapy Disposes of USD 358,084 Perspective Therapeutics Common Shares

Reuters
·
Sep 05

Lantheus Holdings Reports Sale of 78,145 Perspective Therapeutics Shares Worth $245,641

Reuters
·
Sep 03

BMO Capital Initiates Perspective Therapeutics at Outperform

MT Newswires Live
·
Aug 19

Perspective Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Aug 15

BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6

MT Newswires Live
·
Aug 14

RBC Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
Aug 12

Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says

MT Newswires Live
·
Aug 11

Wedbush Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
Aug 11

Perspective Therapeutics (CATX) Receives a Buy from Truist Financial

TIPRANKS
·
Aug 11

Perspective Therapeutics price target lowered to $14 from $16 at Piper Sandler

TIPRANKS
·
Aug 11